The Xid defect determines an improved clinical course of murine leishmaniasis in susceptible mice.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

The Xid defect determines an improved clinical course of murine leishmaniasis in susceptible mice.

Int Immunol. 1994 Aug;6(8):1117-24. Unique Identifier : AIDSLINE MED/95071940
Hoerauf A; Solbach W; Lohoff M; Rollinghoff M; Institute of Clinical Microbiology, University of; Erlangen-Nurnberg, Germany.

Abstract: The course of Leishmania major infection in B cell-defective BALB.Xid mice was investigated. Infected BALB.Xid mice showed a significantly slower lesion development compared with BALB/c controls accompanied by a 10- to 30-fold lower parasite burden in lymphatic organs. The B cell immune response, as quantified by anti-leishmanial antibody production and B cell numbers in lymphatic organs, remained significantly lower in BALB.Xid mice as compared with BALB/c control mice. In accordance with disease development, CD4+ T cells from lymph nodes of infected BALB.Xid mice produced 6- to 10-fold more IFN-gamma than the respective T cells of BALB/c mice, when stimulated with leishmanial antigen in vitro. B cells from lymph nodes and the peritoneal cavities of BALB/c mice could be induced to produce 3- to 8-fold more IL-10 than the respective cells from B cell-defective BALB.Xid mice. The data thus indicate that the Xid mutation allows for the development of Th1 cells which confer resistance to infection with L. major. Moreover, the data suggest that B cells contribute to susceptibility to L. major infection in BALB/c mice by skewing the Th cell network towards a Th2 phenotype. Since the difference in B cell-derived IL-10 production between BALB/c and BALB.Xid mice was more prominent in peritoneal B cells, the data support the notion that the skewing of the T cell response may be predominantly mediated by the B1 cell subset.

Keywords: Animal B-Lymphocytes/IMMUNOLOGY Cells, Cultured Flow Cytometry Immunoglobulins/BIOSYNTHESIS Immunologic Deficiency Syndromes/GENETICS/*IMMUNOLOGY Interferon Type II/BIOSYNTHESIS Interleukin-10/BIOSYNTHESIS Leishmania major/*IMMUNOLOGY Leishmaniasis/*IMMUNOLOGY Lymph Nodes/CYTOLOGY/IMMUNOLOGY Mice Mice, Inbred BALB C Peritoneal Cavity/CYTOLOGY Support, Non-U.S. Gov't Th1 Cells/IMMUNOLOGY Th2 Cells/IMMUNOLOGY JOURNAL ARTICLE
950330
M9530808

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .